CRISPR Therapeutics AG (CRSP) Assets Average (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted Assets Average of $2.5 billion for Q1 2026, up 10.65% sequentially from $2.3 billion in Q4 2025, and up 13.22% YoY from $2.2 billion in Q1 2025.
CRISPR Therapeutics AG (CRSP) Assets Average (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Assets Average for 11 years, with the latest figure at $2.5 billion in Q1 2026.
- Quarterly Assets Average rose 13.22% year-over-year to $2.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 13.22% YoY) and the FY2025 annual result came in at $2.3 billion, up 0.8% from the prior year.
- Assets Average improved to $2.5 billion in Q1 2026 per CRSP's latest filing, from $2.3 billion in the prior quarter.
- Over five years, Assets Average peaked at $2.7 billion in Q1 2022 and troughed at $2.1 billion in Q2 2025.
- A 5-year average of $2.3 billion and a median of $2.3 billion in 2025 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 41.53% in 2022, down 17.53% in 2022.
- Over 5 years, Assets Average stood at $2.3 billion in 2022, then decreased by 6.09% to $2.2 billion in 2023, then gained by 4.21% to $2.2 billion in 2024, then increased by 0.28% to $2.3 billion in 2025, then gained by 10.65% to $2.5 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $2.5 billion, $2.3 billion, and $2.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 2.69 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.69 Bn |
| Mar 31, 2026 | 2.50 Bn |
| Dec 31, 2025 | 2.26 Bn |
| Sep 30, 2025 | 2.14 Bn |
| Jun 30, 2025 | 2.10 Bn |
| Mar 31, 2025 | 2.20 Bn |
| Dec 31, 2024 | 2.25 Bn |
| Sep 30, 2024 | 2.30 Bn |
| Jun 30, 2024 | 2.39 Bn |
| Mar 31, 2024 | 2.33 Bn |
| Dec 31, 2023 | 2.16 Bn |
| Sep 30, 2023 | 2.14 Bn |
| Jun 30, 2023 | 2.22 Bn |
| Mar 31, 2023 | 2.24 Bn |
| Dec 31, 2022 | 2.30 Bn |
| Sep 30, 2022 | 2.41 Bn |
| Jun 30, 2022 | 2.53 Bn |
| Mar 31, 2022 | 2.68 Bn |
| Dec 31, 2021 | 2.79 Bn |
| Sep 30, 2021 | 2.86 Bn |